RE:RE:Re: News TodayGreat news, this is perfectly align....
We have GVHD coming this year with their result and starting phase 3.(Market 600 Million Now).
And just when you think this is big you get news like this one.... KAL-1816, this is way bigger then anything else that Kaly has.... the opiod market is looking for an alternative... could this be it...
I know that the actual opiod market is over 25 BILLION $ .... this year alone , and that for the state alone....
This will take a few years, but could be rush due to the Opiod crisis.
Good luck to all
The commercial opportunity for Kalytera’s KAL-1816 molecule for treatment of pain is large. According to a 2016 report by Transparency Market Research, the global pain management therapeutics market is projected to reach USD $83 billion by 2024. Current treatments for pain mainly include non-steroidal anti-inflammatory drugs ("NSAIDs"), such as naproxen, for mild to moderate pain, and opioids, such as morphine, for moderate to severe and chronic pain. Kalytera believes that its product will be suitable for mild to severe pain, without the risks of respiratory suppression and dependence associated with opioid analgesics.